Partnership since January 2023
In January 2023, LLS made an equity investment in BioInvent to "Support Clinical Development of BI-1206 for NHL Indications and BI-1808 for T-Cell Lymphoma Indications Including CTCL."
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
BI-1206 is a novel anti-FcyRIIB antibody currently being studied in two Phase 1/2 trials, in combination with rituximab in NHL (NCT03571568) and in combination with pembrolizumab in solid tumors (NCT04219254).
BI-1808 is an anti-TNFR2 antibody being evaluated in a Phase 1/2a trial, as a single agent and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) in patients with ovarian cancer, non-small cell lung cancer and cutaneous T-cell lymphoma (NCT04752826).
For more information about BioInvent, visit www.bioinvent.com/.
- January 17 2023 - announced selection as partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), aimed at advancing the company’s program to treat blood cancers. The partnership will include access to the unique scientific, clinical and drug development expertise of LLS as well as a strategic capital equity investment from LLS TAP of USD 3 million.